Book Details

Valuation in Life Sciences

Publication year: 2007

ISBN: 978-3-540-45567-7

Internet Resource: Please Login to download book

This book recognizes that there is no consent on how to apply valuation methodologies in life sciences. One of the complicating factors is that, compared to other industries, valuation of biotech innovation is much more demanding. The long 10-15-year development and clinical trials process still represents the main risks faced by any biotech company. Added to that is the fact that getting a drug across the regulatory goal line and receiving Food and Drug Administration approval (or other regulatory agency - proval in the United States or elsewhere in the world) for marketing is no longer good enough.

Subject: Business and Economics, Biotech, Cash-flow, Computerassistierte Detektion, Medtech, Pharma, Radiologieinformationssystem, Real Options, Valuation, Venture Capital, biotechnology, business, development, strategy